Daniel Lochner is CFO at Oyster Point Pharma, Inc. (OYST). They have made 3 open-market trades across 2 companies since 2019, most recently 2026-09-25.
CIK 0001791187
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $730K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TECX | 58,024 | $1.2M |
| OYST | 76,525 | $855K |
| Total | $2.1M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.